Abstract: A deodorant and antimicrobial dispersion is formed of a deodorant and antimicrobial component, a binder resin and an aqueous or oily liquid medium. The deodorant and antimicrobial component comprises an oxide or hydroxide of an alkaline earth metal, hydrated silica, and a cationic surfactant.

Abstract: A formulation for preventing or treating parturient hypocalcemia or milk fever comprises a solution of hydrochloric acid in water, soybean meal, additional feed components and minerals. The feed formulation is prepared by grinding soybean meal to a particle size of 1000 to 2000 microns. A hydrochloric acid solution and feedgrade limestone are blended into the meal to produce the formulation.

Abstract: The treatment is by means of nutritional supplements for the adrenal glands, liver and mast cells. The supplements may include potassium, magnesium, Vit B6, Vit B5, Vit C and EFA. A biological mechanism linking stress and allergies such as hayfever or other perennial or seasonal respiratory allergies is proposed and the effect of the treatment thereon is discussed.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula wherein R1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R3 and R5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: The invention relates to a mixture for use as wound dressing, which comprises:

Abstract: An inorganic antimicrobial composition has the formula AB2O4, wherein A and B are low temperature far infrared irradiating metals, A is Mg, Zn, Mn, Ni, Co, or Fe(II), B is Al, Cr(III), Mn(III) or Fe(III), and O is oxygen. An antimicrobial article is made by coating said composition on a porous honeycomb-shaped substrate. An organic antimicrobial article is made from a quarternary ammonium salt coated on a porous honeycomb-shaped substrate. Processes of making the antimicrobial articles are provided.

Abstract: A tablet for the transmucosal administration of nicotine. The nicotine is in one or more layers upon a non-nicotine containing matrix. The nicotine layers rapidly dissolve in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces. The short, rapid pulse of nicotine is similar to that given by cigarette smoking. The nicotine may be provided in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine layers.

Abstract: Pharmaceutically acceptable compositions suitable for releasing magnesium ions to an organism, such as organic or inorganic magnesium salts or complexes thereof, are used to prevent and to treat neoplastic and autoimmune diseases, whose origin can be attributed to magnesium depletion. For the new therapeutic indications the magnesium based product, preferably magnesium pyrophosphate, is usually administered orally or parenterally, preferably in association with vitamin B6.

Abstract: The invention provides a medicament for topically treating acute bacterial infections in the oral mucosa, and methods of use. The medicament comprises a dry dosage (such as a troche or powder) of one or more antibacterial agents and, preferably, one or more polyvalent metal compounds. The medicament is directly applied to the site of the infection and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibacterial agent to the infected oral tissue. Further, in a preferred embodiment the medicament directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the infected area, thereby forming a protective barrier over the infected oral tissue.

Abstract: Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelates, and the metal amino acid chelate growth facilitator, promoter and enhancer prepared by the process.

Abstract: Disclosed herein are compositions which are highly effective rodenticides. The compositions include a plurality of glass whiskers which rodents are naturally attracted to for purposes of nest building, or are otherwise induced to pick up in their mouths. Upon biting the whiskers for either transport or eating, the rodents oral mucosa becomes irritated, often to the extent that the rodents are unable to subsequently eat without excruciating pain. Hence, the rodents death by starvation is inevitable.

Abstract: Compositions for the treatment and prevention of migraine or stress headaches wherein there is supplied a combination of potassium, magnesium and pyridoxine optionally in association with other nutrients and/or simple analgesics.

Abstract: A nutritional supplement for the prevention and treatment of excessive intestinal permeability is provided. The treatment includes a dietary regimen of nutritional buffers, amino acid chelates, minerals and vitamins. Other components may include antioxidants, free radical scavengers, beneficial organisms, and intestinal tract-soothing herbs.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Abstract: The present invention is directed to a method of inhibiting the growth of disease organisms on and in plants by directly applying an aqueous solution comprising urea and at least one water-soluble salt of a divalent cation and a monovalent anion to the seeds, stems, bark, leaves, seed heads or sub-surface root zones of said plants. The weight percent ratio of urea to divalent cation in these solutions should be from about 0.25-10.0 to 1.0. Preferred divalent cations include those of the alkaline earth metals and the transition metals. Most preferred are calcium, magnesium, zinc, manganese, copper, iron, cobalt, nickel and mixtures thereof. Preferred anions include nitrate, chloride, bromide and mixtures thereof. In more preferred solutions, the ratio of urea to divalent cation is from about 2.0-7.0 to 1.0. Particularly preferred solutions include calcium chloride as the water-soluble salt. Optionally, a second water-soluble salt of a divalent cation and a monovalent anion may be included.

Abstract: An antacid composition containing 20 to 75 weight percent calcium carbonate, 0.1 to 10 weight percent magnesium hydroxide, and 0.5 to 10 weight percent potassium hydroxide is disclosed. A method for neutralizing excess stomach acid by oral administration of the antacid composition of the invention is also disclosed.

Abstract: A composition for use in the rehydration and treatment of scours in calves. The composition includes fiber, electrolytes and three energy sources. The energy sources are sugar, medium chain triglycerides and glycine, present in a combined amount of about 14 percent by weight.

Abstract: An inorganic anticmirobial composition has the the formula AB.sub.2 O.sub.4 wherein A and B are low temperature far infrared irradiating metals, A is Mg, Zn, Mn, Ni, Co, or Fe(II), B is Al, Cr(III), Mn(III) or Fe(III), and O is oxygen. An antimicrobial article is made by coating said composition on a porous honeycomb-shaped substrate. An organic antimicrobal article is made from a quarternary ammonium salt coated on a porous honeycomb-shaped substrate. Processes of making the antimicrobial articles are provided.

Abstract: The invention concerns a highly concentrated mineralised natural complex, characterised by at least one main mineral element quantified with nutritional and/or dietetic integrator properties and by other mineral elements obtained in the complex from the mineralization of vegetal and/or animal products. Moreover, it concerns the method for its production consisting in using vegetal and/or animal organic substances, having a high content of oligominerals, in carrying out their fragmentation, their mixing and the mineralization until the inorganic part is completely separated from the organic part, and then in transforming the aforesaid inorganic part in forms of easy commercialization.

Abstract: The invention provides a synthetic bone precursor material comprising amorphous calcium phosphate and a constituent that inhibits the crystallisation of calcium hydroxyapatite to amorphous calcium phosphate. The synthetic bone precursor may comprise a material of formula CaxMgyPO4 wherein Mg acts as an inhibitor for crystallisation. Other crystallisation inhibitors such as pyrophosphate may be present. The inhibitor is capable of dissolving in physiological saline. Loss of inhibitor from the precursor allows crystallisation of hydroxyapatite. The invention relates to use of a synthetic bone precursor to form bone in vivo, by a transformation of the amorphous precursor material to crystalline hydroxyapatite bone material by the leaching action on inhibitory ions body fluids. it is envisaged that the material will be useful in facilitating bone repair, inducing bone formation or assisting in the attachment of prostheses.

Abstract: The invention provides a medicament for topically treating aphthous ulcers in the oral mucosa, and methods of use. The medicament comprises a troche or powder comprising a dry dosage of one or more antibiotics and, preferably, one or more polyvalent metal compounds. The troche or powder is directly applied to the aphthous ulcer and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibiotic to the ulcerated oral tissue. Further, in a preferred embodiment the troche/powder directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the aphthous ulcer, thereby forming a protective barrier over the ulcerated oral tissue.

Abstract: A nutritional supplement for the prevention and treatment of excessive intestinal permeability is provided. The treatment includes a dietary regimen of nutritional buffers, amino acid chelates, minerals and vitamins. Other components may include antioxidants, free radical scavengers, beneficial organisms, and intestinal tract-soothing herbs.

Abstract: Composition and method of using the same for preventing or treating microalbuminuria in a warm blooded animal in which the composition contains effective amounts of vitamin E, folic acid, a magnesium-releasing compound, a chromium-releasing compound and vitamin B-12.

Abstract: The present invention pertains generally to the field of Public Health, including the prevention and treatment of coronary heart disease which is currently the first cause of death in the American population. More specifically, the present invention concerns a total modular system of multivitamin and mineral supplementation composed of 7 distinct modules for improving public health by insuring adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to, for example, lifestyle factors and common inadequate dietary patterns. A module, as used herein throughout, is defined as a separate and distinct combination of vitamin-mineral and other health promoting compounds which are directed to specific target populations. The formulations of the present invention which, when combined in one capsule or tablet or as separate modules, exert a joint and enhancing effect on the major pathogenetic factors involved in the atherosclerotic process.

Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: The invention describes an oral anti-acid paste comprising anti-acid compound in a slow releasing carrier medium which disperses the anti-acid, and releases the anti-acid from the paste upon contact with the aqueous media such as saliva. The paste can be used by placement in the mouth for slow release of the anti-acid into the saliva thereby contacting the mucosa of the esophagus to inhibit irritation to the mucosa due to excess acid.

Abstract: A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.

Abstract: An aqueous cosmetic composition containing uric acid in a stably solubilized state together with 0.01 to 1.3% by weight of one or more amphoteric surfactants selected from the group consisting of (a) lauric acid amide propyl betaine, (b) alkyl carboxymethyl hydroxyethyl imidazolinium betaine, (c) coconut oil fatty acid amide propylmethylaminoacetic acid betaine, (d) sodium salt of coconut oil fatty acid acyl carboxymethyl hydroxyethyl ethylenediamine, (e) lauryl dimethylaminoacetic acid betaine and (f) coconut oil alkyl betaine, an alkali and water. The composition is adjusted to pH equal to or higher than pK.sub.1 of uric acid with the alkali to solubilize uric acid. A method for stably solubilizing uric acid in an aqueous cosmetic composition is also disclosed.

Abstract: A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a therapeutically effective amount of guanidinothiazole compound; and a therapeutically effective amount of an antacid wherein the pharmaceutical and an antacid are separated by a barrier which is substantially impermeable to an antacid.

Abstract: Aqueous pharmaceutical solutions suitable for injection into a host, having improved injection site toleration, comprise danofloxacin or its pharmaceutically acceptable salts and a magnesium or zinc compound. The zinc compound in addition requires the presence of a co-solvent.

Abstract: The present invention provides tasteless liquid compositions for oral ingestion of pharmacologically active agents having basic moieties, wherein the compositions contain the basic pharmacologically active agent in the form of a salt of a pharmacologically acceptable organic acid, a silicate adsorbent and a sufficient amount of water to suspend the foregoing components. There are also provided methods of making these compositions.

Abstract: The present invention provides a dialysis solution that contains amino acids for treating and/or preventing malnutrition in a peritoneal dialysis patient. The amino acid composition is optimized to minimize metabolic acidosis while normalizing amino acid plasma profiles.

Abstract: The invention relates to the combined use of ketoprofen and specific inorganic basic substances with an improved quality of action.

Abstract: Hydrolyzed gelatin has been found to provide an improvement in taste and mouthfeel when incorporated in small amounts into chewable tablets containing ingredients requiring taste masking. Medicinals and nutritional supplements may now be prepared as chewables for those who find tablets difficult to swallow, for example children and older adults, or for those who prefer the convenience. There is a particularly large improvement in the taste and mouthfeel of chewables incorporating magaldrate and/or calcium carbonate.

Abstract: A composition for oral preparations, having a complex formed by dispersing or dissolving an unpleasantly tasting basic drug and a functional polymer compound in a substance having a low melting point, 10 to 70% by weight, based on the composition, of sugar alcohol and 0.1 to 7% by weight, based on the composition, of basic oxide. The composition for oral preparation is excellent in masking unpleasantly tasting basic drugs and has excellent performance in biological use.

Abstract: The present invention provides a dialysis solution that contains amino acids for treating and/or preventing malnutrition in a peritoneal dialysis patient. The amino acid composition is optimized to minimize metabolic acidosis while normalizing amino acid plasma profiles.

Abstract: An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.

Abstract: A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.

Abstract: Hydrolyzed gelatin has been found to provide an improvement in taste and mouthfeel when incorporated in small amounts into chewable tablets containing ingredients requiring taste masking. Medicinals and nutritional supplements may now be prepared as chewables for those who find tablets difficult to swallow, for example children and older adults, or for those who prefer the convenience. There is a particularly large improvement in the taste and mouthfeel of chewables incorporating magaldrate and/or calcium carbonate.

Abstract: Antiacid pharmaceutical compositions in the form of suspensions containing sucralphate gel as an active ingredient combined with suitable excipients and/or diluents.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist, and antacid, optimally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: The present invention relates to dietary supplements for supplementing the dietary needs of women and preventing or reducing life stage associated health risks during each of their principal adult life stages (pre-perimenopause, perimenopause and menopause, or post-menopause).

Abstract: An antacid composition comprises, as antacid ingredients, a hydrotalcite and dihydroxyaluminium aminoacetate in such a ratio that the former/the latter equals 30/70 to 90/10 (by weight). The composition may further comprises a readily acting or rapid effecting antacid ingredient such as a magnesium hydroxide in an amount of 10 to 50% by weight. The antacid composition is improved in antacid properties and rapid effecting properties, and is useful as a pharmaceutical composition comprising the antacid composition, a carrier, an additive, an additional pharmaceutically active ingredient and so on. The total amount of the antacid ingredients in the pharmaceutical composition may be 10% by weight or more. The pharmaceutical composition may be formed into a fine granule or a granule with utilizing granulation, or into a tablet by compression-molding.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: A composition for the treatment of premenstrual syndrome comprising an effective amount of calcium, magnesium, an analgesic and a diuretic sufficient to reduce the symptoms of premenstrual syndrome.

Abstract: An anticoagulant for blood contains sodium hydroxide, citric acid and sodium hexametaphosphate. A method of preventing the clotting of blood using the anticoagulant also is disclosed.

Abstract: A method of installing in a building a suspension containing paramagnetic susceptible elements consisting essentially of:(A) providing in a non-metallic container 5-12 pounds of a composition consisting essentially of (i) 30-99 wt % of a carbonate or a mixture of two or more carbonates selected from the group consisting of magnesium carbonate, calcium carbonate, strontium carbonate, barium carbonate and mixtures thereof, wherein the carbonate or mixture of carbonates are in powder form, (ii) 1-70 wt % of activated carbon in powder form, (iii) 0.